READ THE FULL LGVN RESEARCH REPORT
Longeveron (NASDAQ:LGVN) is a company that should be getting more attention from investors for the treatments that could be coming to market in the near future. The next 12-18 months will prove to be critical for the company, and we urge investors to take a look at LGVN in advance of the upcoming potential catalysts. LGVN has made substantial progress with its signature treatment, Lomecel-B, also known as laromestrocel, in treating both HLHS and Alzheimer’s Disease and we are looking forward to the year ahead when we expect to receive exciting news.
Company management continues to push the company forward, recently announcing that LGVN has licensed a patent from the University of Miami that protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells. In plain English, these cells are able to differentiate into human cardiac muscle cells. This creates the potential for a treatment that is safer than existing techniques to derive new cardiac heart muscle cells. This move by management appears to us to be a perfect complement to the company’s existing treatment line and should advance the company’s ability to treat devastating heart conditions.
This follows news that the company has full enrollment in the pivotal Phase 2b clinical trial of laromestrocel for the treatment of Hypoplastic Left Heart Syndrome (HLHS). This marked a major milestone for the company. Due to the rare nature of the condition, finding patients eligible and willing to participate in the trial was a major challenge and now that it’s completed, the clock toward approval can start. Along with the enrollment announcement, company management outlined the expected timeline, with top-line results anticipated in 3Q2026, followed by the filing of a Biological License Application, provided the testing results are positive, which we fully expect. As a reminder, laromestrocel has been granted Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation by the FDA.
That’s not the only line of treatment being pursued by the company as management recently announced that it completed a “positive” Type B Meeting with the FDA regarding advancing laromestrocel for the purpose of treating Alzheimer’s Disease. During the meeting, the FDA and the company reached alignment on the study design for a single, pivotal, seamless adaptive Phase 2/3 clinical trial. Additionally, something we always like to hear about the approval process, the FDA agreed to consider a Biological License Application (BLA) based on positive interim trial results, which accelerate the path to what we believe will be the approval of laromestrocel as a treatment for Alzheimer’s.
As a reminder, our optimism is well founded based on trial results that we’ve written about recently. For example, the Phase 2a CLEAR-MIND study results showed a favorable safety profile, absence of amyloid-related imaging abnormalities (ARIA) with Lomecel-B TM administration, and several domains of potential clinical efficacy, including cognition, function, quality of life, and reduction in brain atrophy. The results of the CLEAR-MIND trial formed the basis for the FDA RMAT designation. Another reminder that the RMAT designation is an important milestone, allowing the company better access to the FDA and accelerating the pathway to approval.
Summary
We continue to believe that Longeveron is an exciting clinical-stage company and investors aren’t appropriately appreciating the game-changing potential Lomecel-B may be able to have on multiple serious medical conditions. As a result of the prudent decisions made by management, we believe laromestrocel will ultimately have a substantial impact on the health situations of thousands of patients. We believe the stock continues to be underpriced as investors aren’t appreciating the potential of Lomecel-B and encourage investors to take a look at LGVN.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
